Master the 2022 AHA/ACC/HFSA heart failure guidelines for primary care — ARNI, beta-blocker, MRA, SGLT2i, and new HFpEF therapies including SGLT2 inhibitors and GLP-1 receptor agonists. Earn CME credits.
Heart failure with preserved ejection fraction (HFpEF) now accounts for more than half of all heart failure diagnoses in the United States, and the proportion continues to rise alongside the obesity epidemic. For decades, clinicians managing this phenotype had few effective pharmacologic tools — spironolactone and SGLT-2 inhibitors offered modest benefit in selected patients, but
Primary care physicians—family physicians, internists, NPs, and PAs—are the backbone of healthcare. On any given clinic day, a PCP treats a wide range of issues: UTIs, URIs, back pain, rashes, warts, hypertension follow-ups, dizziness, and more. Ideally, we would stay up to date on every possible condition. But in reality, modern primary care makes that
Why Primary Care Physicians Should Prioritize the Top Chronic Diseases Read More »
A Missed Opportunity: SGLT2 inhibitors in Heart Failure Care Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have transformed heart failure management, reducing both hospitalizations and cardiovascular deaths across the ejection fraction spectrum. Guidelines now recommend SGLT2i as foundational therapy for patients with heart failure—yet real-world prescribing still lags far behind. A new retrospective cohort study of over
SGLT2 Inhibitors in Heart Failure: Underused Even Among Cardiologists? Read More »
